Study shows potential of ctDNA as biomarker for immunotherapy response in GU cancers

Albert Jang, MD, discusses the promise of using ctDNA to determine whether patients with advanced genitourinary cancers are responding to immune checkpoint inhibitors.

Albert Jang, MD, a 3rd-year internal resident physician at Tulane University, discusses the study, “Prospective Evaluation Of Circulating Tumor Dna (ctDNA) in Detecting Early Progression on Immune Checkpoint Inhibitors in Patients With Advanced Genitourinary Cancers,” which he shared at the 2022 AUA Annual Meeting.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.